Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Thoracic Oncology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.jtho.2017.10.020PMID 29127022
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy

  2017cited by this paper
• The “cancer immunogram”

  2016cited by this paper
• Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

  2016cited by this paper
• Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade.

  2016cited by this paper
• Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

  2016cited by this paper
• Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.

  2016cited by this paper
• Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

  2016cited by this paper
• Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration

  2016cited by this paper
• Adjuvant therapy for nonsmall cell lung cancer: recent advances and future perspectives

  2016cited by this paper
• Adjuvant immunotherapy in resected early non-small cell lung cancer-battle lost, hopefully not the war!

  2016cited by this paper
• Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer.

  2016cited by this paper
• The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification.

  2016cited by this paper
• Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

  2015cited by this paper
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

  2015cited by this paper
• Molecular and genetic properties of tumors associated with local immune cytolytic activity.

  2015cited by this paper
• Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.

  2015cited by this paper
• Classifying Cancers Based on T-cell Infiltration and PD-L1.

  2015cited by this paper
• Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection.

  2015cited by this paper
• Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival.

  2015cited by this paper
• Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer

  2015cited by this paper
• Adjuvant chemotherapy for resected early-stage non-small cell lung cancer.

  2015cited by this paper
• Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication

  2014cited by this paper
• Comprehensive molecular profiling of lung adenocarcinoma

  2014cited by this paper
• Associations Between Mutations and Histologic Patterns of Mucin in Lung Adenocarcinoma: Invasive Mucinous Pattern and Extracellular Mucin Are Associated With KRAS Mutation

  2014cited by this paper
• The prognostic and predictive value of solid subtype in invasive lung adenocarcinoma

  2014cited by this paper
• Genetic basis for clinical response to CTLA-4 blockade in melanoma.

  2014cited by this paper
• Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

  2014cited by this paper
• MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

  2014cited by this paper
• Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma

  2014cited by this paper
• Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.

  2013cited by this paper
• The Mutational Landscape of Adenoid Cystic Carcinoma

  2013cited by this paper
• KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma

  2013cited by this paper
• The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival.

  2012cited by this paper
• Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.

  2012cited by this paper
• Adjuvant immunotherapy for non-small cell lung cancer.

  2012cited by this paper
• Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases

  2011cited by this paper
• International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

  2011cited by this paper
• The mutation spectrum revealed by paired genome sequences from a lung cancer patient

  2010cited by this paper
• Adjuvant immunotherapy for solid tumors: from promise to clinical application

  2002cited by this paper

• Medical expenses and influencing factors in lung cancer patients: a comparative analysis between surgical and non-surgical cases from Xiamen, China

  2026cites this paper
• GSDME-mediated pyroptosis modulates the immunosuppressive microenvironment in lung adenocarcinoma.

  2026cites this paper
• The difference in tumor immune microenvironment and IFN-γ response between solid and non-solid adenocarcinoma

  2025cites this paper
• Comparative survival outcomes between EGFR-wildtype and EGFR-mutant lung adenocarcinoma following neoadjuvant chemoimmunotherapy: a retrospective cohort study from national cancer center in China

  2025cites this paper
• Gene expression in tumor and adjacent normal tissues in lung adenocarcinoma subtypes

  2025cites this paper
• Multi‑omics analysis identifies different molecular subtypes with unique outcomes in early-stage poorly differentiated lung adenocarcinoma

  2025cites this paper
• PD‐L1 Scoring Models for Non‐Small Cell Lung Cancer in China: Current Status, AI‐Assisted Solutions and Future Perspectives

  2025cites this paper
• Translating premalignant biology to accelerate non-small-cell lung cancer interception

  2025cites this paper
• Impact of histopathological subtypes on invasive lung adenocarcinoma: from epidemiology to tumour microenvironment to therapeutic strategies

  2025influential citation
• IL4I1⁺ Macrophages and TDO2⁺ Myofibroblasts Drive AhR‐Mediated Immunosuppression and Ferroptosis Resistance in Solid Predominant Lung Adenocarcinoma

  2025cites this paper
• Lung adenocarcinoma: selection of surgical approaches in solid adenocarcinoma from the viewpoint of clinicopathologic features and tumor microenvironmental heterogeneity

  2024cites this paper
• Senescence cell signature associated with poor prognosis, epithelial–mesenchymal transition, solid histology, and spread through air spaces in lung adenocarcinoma

  2024cites this paper
• Construction of a 12-Gene Prognostic Risk Model and Tumor Immune Microenvironment Analysis Based on the Clear Cell Renal Cell Carcinoma Model

  2024cites this paper
• High expression of eukaryotic elongation factor 1‐alpha‐2 in lung adenocarcinoma is associated with poor prognosis

  2024cites this paper
• Molecular epidemiology study of programmed death ligand 1 and ligand 2 protein expression assessed by immunohistochemistry in extensive-stage small-cell lung cancer

  2024cites this paper
• Multi-omics analysis unravels the underlying mechanisms of poor prognosis and differential therapeutic responses of solid predominant lung adenocarcinoma

  2023cites this paper
• Evolutionary characterisation of lung adenocarcinoma morphology in TRACERx

  2023cites this paper
• Establishment and validation of nomograms for predicting survival of lung invasive adenocarcinoma based on the level of pathological differentiation: a SEER cohort-based analysis

  2023cites this paper
• High‑risk pathological subtype associated FAM83A‑AS1 promotes malignancy and glycolysis of lung adenocarcinoma via miR‑202‑3p/HK2 axis

  2023cites this paper
• 不同病理亚型浸润性非黏液腺癌的研究进展

  2023cites this paper
• Clinical implications and molecular features of tertiary lymphoid structures in stage I lung adenocarcinoma

  2023cites this paper
• CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy

  2023cites this paper
• Genetic, DNA methylation, and immune profile discrepancies between early-stage single primary lung cancer and synchronous multiple primary lung cancer

  2023cites this paper
• A Novel Radiopathological Grading System to Tailor Recurrence Risk for Pathologic Stage IA Lung Adenocarcinoma.

  2022cites this paper
• The integrated landscape of eRNA in gastric cancer reveals distinct immune subtypes with prognostic and therapeutic relevance

  2022cites this paper
• Comparative profiling of single-cell transcriptome reveals heterogeneity of tumor microenvironment between solid and acinar lung adenocarcinoma

  2022cites this paper
• Programmed Death Ligand 1 Expression in Lung Adenocarcinoma: An Analysis of the Histomorphological Features

  2022cites this paper
• Evaluation of tumor microenvironmental immune regulation and prognostic in lung adenocarcinoma from the perspective of purinergic receptor P2Y13

  2021cites this paper
• Clinical significance of tumor necrosis and viability in non-small cell lung cancer

  2021cites this paper
• Adenocarcinoma of High-Grade Patterns Associated with Distinct Outcome of First-Line Chemotherapy or EGFR-TKIs in Patients of Relapsed Lung Cancer

  2021cites this paper
• TGFβ Signaling Activated by Cancer-Associated Fibroblasts Determines the Histological Signature of Lung Adenocarcinoma

  2021cites this paper
• Significant difference in recurrence according to the proportion of high grade patterns in stage IA lung adenocarcinoma

  2021cites this paper
• Adenocarcinoma of High-Grade Patterns Associated with Distinct Outcome of First-Line Chemotherapy or EGFR-TKIs in Patients of Relapsed Lung Cancer

  2021cites this paper
• Proteomic Analyses Identify Differentially Expressed Proteins and Pathways Between Low-Risk and High-Risk Subtypes of Early-Stage Lung Adenocarcinoma and Their Prognostic Impacts

  2021cites this paper
• Immune Microenvironment Signatures as Biomarkers to Predict Early Recurrence of Stage Ia-b Lung Cancer

  2021cites this paper
• Advances in deubiquitinating enzymes in lung adenocarcinoma

  2021cites this paper
• Comparative analysis of machine learning approaches to classify tumor mutation burden in lung adenocarcinoma using histopathology images

  2021cites this paper
• Identification of an immune-related six-long noncoding RNA signature as a novel prognosis biomarker for adenocarcinoma of lung

  2020cites this paper
• Proteomic analyses identify differentially expressed proteins and pathways between low-risk and high-risk subtypes of early-stage lung adenocarcinoma and their prognostic impacts.

  2020cites this paper
• Clinical implication of minimal presence of solid or micropapillary subtype in early‐stage lung adenocarcinoma

  2020cites this paper
• PD-L1 protein expression is positively correlated with the solid predominant subtype, high MIB-1 labeling index and p53 expression and negatively correlated with EGFR mutations in lung adenocarcinoma.

  2020cites this paper
• Identification of immune landscape signatures associated with clinical and prognostic features of hepatocellular carcinoma

  2020cites this paper
• Morphological, immune and genetic features in biopsy sample associated with the efficacy of pembrolizumab in patients with non-squamous non-small cell lung cancer

  2020cites this paper
• The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma.

  2020cites this paper
• Association of histologic subtypes with genetic alteration and PD-L1 expression in pulmonary adenocarcinoma

  2020cites this paper
• Gene expression profiling by targeted RNA sequencing in pathological stage I lung adenocarcinoma with a solid component.

  2020cites this paper
• Prognostic implications of programmed death ligand 1 expression in resected lung adenocarcinoma: a systematic review and meta-analysis.

  2020cites this paper
• A gene expression-based immune signature for lung adenocarcinoma prognosis

  2020cites this paper
• Predicting and Visualizing STK11 Mutation in Lung Adenocarcinoma Histopathology Slides Using Deep Learning

  2020cites this paper
• CYLD expression in dendritic cells involved in the immunoregulation of pulmonary adenocarcinoma via NF-κB pathway

  2020cites this paper
• Somatic Alteration Burden Involving Non-Cancer Genes Predicts Prognosis in Early-Stage Non-Small Cell Lung Cancer

  2019cites this paper
• Tumor mutational burden in lung cancer: a systematic literature review

  2019cites this paper
• Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation

  2019cites this paper
• Integrating genetic mutations and expression profiles for survival prediction of lung adenocarcinoma

  2019cites this paper
• Profiling the Tumour Immune Microenvironment in Pancreatic Neuroendocrine Neoplasms with Multispectral Imaging Indicates Distinct Subpopulation Characteristics Concordant with WHO 2017 Classification

  2018cites this paper
• Toward innovative combinational immunotherapy: A systems biology perspective.

  2018cites this paper
• Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation

  2018cites this paper
• Translating the biology of lung premalignancy to accelerate lung cancer interception.

  year unknowncites this paper